Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: The clinical features of AML patients highly expressed TBCB . (A) Transcriptional levels of TBCB in thirty-three different cancers. Data was originated from TCGA and GTEx database. (B) The TBCB mRNA levels of AML patients in comparison with normal subjects. Data was originated from TCGA-LAML and GTEx database. (C-D) The differentially expression of TBCB between AML patients and normal subjects from GSE9476 (C) and GSE13159 (D). (E) RT-qPCR analysis for transcriptional levels of TBCB in BMMNC from AML patients (n = 9) relative to healthy donors (n = 14). Expression levels are normalized to 18S. (F) ROC analysis of TBCB in TCGA-LAML and GTEx datasets. (G-J) Significant clinical features were demonstrated, including count of white blood cells (G), proportions of PB blasts (H) and BM blasts (I), mutation rate of FLT3 (J). * p < 0.05; ** p < 0.01; *** p < 0.001.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Comparison, Expressing, Quantitative RT-PCR, Mutagenesis

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: Clinical characteristics with diverse TBCB expression levels in AML patients

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing, Mutagenesis

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: High TBCB expression correlated with unfavorable prognosis. (A) Kaplan-Meier survival curve of OS was delineated for AML patients grouped into high versus low expressed populations in line accordance with the median expression of TBCB . Data was originated from TCGA-LAML dataset. (B) Validation of OS for TBCB in the entirely independent cohort GSE37642 (n = 136). (C-D) Forest plots of OS for AML patients from univariate (C) and multivariable (D) analysis. (E) Nomogram based on integrating TBCB and other meaningful prognostic factors of AML. (F) Calibration of the nomogram. (G-I) The DCA curves of the nomogram at 1 year (G), 2 years (H), and 3 years (I).

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing, Biomarker Discovery

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: DEGs and their functional pathways enrichment analysis. (A) Volcano plot showing TBCB -related DEGs, |log 2 FC| ≥ 0.59, p -adjust< 0.05. (B) The bar diagrams display the top five terms for each GO category and KEGG analysis of the up-regulated DEGs, including biological processes (left), cellular components (medium), and KEGG pathways (right). (C-D) Bubble plot (C) and chord plot (D) showing the top 3 BP terms. (E) The first 10 gene sets of GSEA analysis using the Reactome of C2 in MSigDB database. Immune-related gene sets were marked with red. (F) GSEA analysis of immune-related gene sets in up-regulated DEGs.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Functional Assay

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: Establishment of PPI network and the clinical significance of hub genes. (A-C) The top15 hub genes were acquired with PPI network on the base of MCC (A), MNC (B) and EPC (C) algorithms. (D) The Venn diagram shows the overlap among the top 15 genes sorted by the three algorithms. (E) Expression levels of six hub genes (ITGAM, ITGB2, ITGAX, SPI1, TYROBP, CD68) in TCGA-LAML and GTEx database. (F-G) Co-expression heat map (F) and correlation scatter plots (G) of TBCB with six hub genes. (H-J) The OS in AML patients, splitting into two populations with high versus low expression in the light of the median expression levels of three hub genes, were created by Kaplan-Meier analysis. ITGAM (H), ITGB2 (I), ITGAX (J). * p < 0.05, *** p < 0.001.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: Correlationships between TBCB expression level and infiltrating immune cells, immune checkpoint in AML. (A) The relationship between the mRNA level of TBCB and twenty four infiltrating immune cells were examined by Spearman's correlation. (B) Correlation scatter plots for nine immune infiltrating cells positively linked to TBCB transcription level. (C-D) Co-expression heat map (C) and correlation scatter plots (D) of TBCB gene with six momentous immune checkpoint molecules in AML. (E) Expression levels of ligands for inhibitory NK cell receptors ( HLA-E , HLA-G and LGALS9 ) in AML. Data was originated from TCGA-LAML and GTEx database. (F) Correlation scatter plots of TBCB gene with three ligands for inhibitory NK cell receptors in AML. * p < 0.05, ** p < 0.01, *** p < 0.001.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: UP-regulated DEGs with high versus low TBCB expression involved in cell proliferation and apoptosis gene sets in AML patient. (A) Chord plot showing the relevant GO terms of cell proliferation and apoptosis gene sets. (B-C) The Kaplan-Meier survival curves of OS (B) and correlation analysis with TBCB expression (C) for nine genes related to cell proliferation and apoptosis.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: The effects of TBCB knockdown on cell proliferation in AML human cell lines. (A) RT-qPCR analysis for transcriptional levels of TBCB in AML cell line THP1 (left) and Kasumi-1 (right) transduced with NC-siRNA or siTBCB oligonucleotides. Expression levels are normalized to 18S. (B) Western blotting for TBCB expression in THP1 (left) and Kasumi-1 (right) cell lines transduced with NC-siRNA or siTBCB oligonucleotides. (C-D) Proliferation curves of control and siTBCB groups in THP1 (C) and Kasumi-1 (D) cell lines were measured by CCK8. (E-H) The apoptosis analysis of AML cell lines transfected with siTBCB and NC-siRNA. Representative flow cytometry plots of apoptotic ratio in THP1 (E) and Kasumi-1 (G) cell lines. Statistical analysis of apoptotic ratio in THP1 (F) and Kasumi-1 (H) cell lines. (I-L) The cell cycle analysis of AML cell lines transfected with siTBCB and NC-siRNA. Representative flow cytometric analysis of cell cycle in THP1 (I) and Kasumi-1 (K) cell lines. Quantification of G0, G1, S, G2 and M phases in THP1 (J) and Kasumi-1 (L) cell lines. All statistical values were presented as the means ± SEM. n = 3, * p < 0.05, ** p < 0.01, *** p < 0.001, by one-way ANOVA.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Knockdown, Quantitative RT-PCR, Transduction, Expressing, Western Blot, Control, Transfection, Flow Cytometry, Cell Cycle Assay

Journal: Journal of Cancer

Article Title: High Expression of Microtubule-associated Protein TBCB Predicts Adverse Outcome and Immunosuppression in Acute Myeloid Leukemia

doi: 10.7150/jca.84215

Figure Lengend Snippet: Prediction of drug sensitivity based on TBCB expression. (A) CCT018159. (B) 17-AAG. (C) JNJ-268541653. (D) OSU-03012. (E) AG-0140699. (F) Talazoparib. (G) CP724714. (H) Erlotinib. (I) MLN4924. (J) VX-11e. (K) ATRA. (L) Midostaurin. (M) Cytarabine. (N) Sorafenib. (O) Doxorubicin. * p < 0.05, * p < 0.01, *** p < 0.001.

Article Snippet: The siRNA oligonucleotides targeting TBCB (siTBCB) or negative control (NC-siRNA) were synthesized by Suzhou GenePharma Co.,Ltd (Suzhou, China) and transfected into AML cell lines by LipofectamineTM 3000 transfection kit (L3000015, Invitrogen, USA).

Techniques: Expressing